V Praveen1, C K M Tripathi. 1. Division of Fermentation Technology, Central Drug Research Institute, Lucknow, India.
Abstract
AIMS: To isolate and characterize bioactive metabolites produced by a micro-organism isolated from a soil sample associated with the roots of a medicinal plant, Azadirachta indica. METHODS AND RESULTS: Morphological, cultural, physiological and 16S rRNA homology studies revealed that the organism showed 99% similarity with Streptomyces griseoruber NBRC 12873. One bioactive metabolite (Py2) isolated from the fermented broth was characterized as actinomycin-D (act-D). It showed high activity against various gram-positive and gram-negative bacterial cultures, Mycobacterium tuberculosis H37Rv and human neoplastic cells in vitro using standard protocols. CONCLUSIONS: The isolated strain S. griseoruber produced act-D predominantly (210 mg l(-1), c. 88% of the crude) under nonoptimized growth conditions. SIGNIFICANCE AND IMPACT OF THE STUDY: Streptomyces griseoruber may be exploited as a potential source for the commercial production of act-D, as this strain is not reported to produce act-D. Further investigations on the strain for commercial application will be of immense pharmaceutical importance.
AIMS: To isolate and characterize bioactive metabolites produced by a micro-organism isolated from a soil sample associated with the roots of a medicinal plant, Azadirachta indica. METHODS AND RESULTS: Morphological, cultural, physiological and 16S rRNA homology studies revealed that the organism showed 99% similarity with Streptomyces griseoruber NBRC 12873. One bioactive metabolite (Py2) isolated from the fermented broth was characterized as actinomycin-D (act-D). It showed high activity against various gram-positive and gram-negative bacterial cultures, Mycobacterium tuberculosis H37Rv and human neoplastic cells in vitro using standard protocols. CONCLUSIONS: The isolated strain S. griseoruber produced act-D predominantly (210 mg l(-1), c. 88% of the crude) under nonoptimized growth conditions. SIGNIFICANCE AND IMPACT OF THE STUDY: Streptomyces griseoruber may be exploited as a potential source for the commercial production of act-D, as this strain is not reported to produce act-D. Further investigations on the strain for commercial application will be of immense pharmaceutical importance.
Authors: Kendall Souder; Emma J Beatty; Siena C McGovern; Michael Whaby; Emily Young; Jacob Pancake; Daron Weekley; Justin Rice; Donald A Primerano; James Denvir; Joseph Horzempa; Deanna M Schmitt Journal: Antibiotics (Basel) Date: 2021-08-17
Authors: Dongyang Wang; Cong Wang; Pengyan Gui; Haishan Liu; Sameh M H Khalaf; Elsayed A Elsayed; Mohammed A M Wadaan; Wael N Hozzein; Weiming Zhu Journal: Front Microbiol Date: 2017-06-28 Impact factor: 5.640
Authors: Kamal A Qureshi; Avinash D Bholay; Pankaj K Rai; Hamdoon A Mohammed; Riaz A Khan; Faizul Azam; Mariusz Jaremko; Abdul-Hamid Emwas; Piotr Stefanowicz; Mateusz Waliczek; Monika Kijewska; Ehab A Ragab; Medhat Rehan; Gamal O Elhassan; Md Jamir Anwar; Dinesh K Prajapati Journal: Sci Rep Date: 2021-07-15 Impact factor: 4.379